XML 32 R25.htm IDEA: XBRL DOCUMENT v3.26.1

Revenue (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregated Revenue

The following table presents our disaggregated revenue for the periods presented (in thousands):

		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
MRD revenue
Service revenue		$	66,168			$	44,438			$	124,261			$	83,659
Regulatory milestone revenue			—				5,500				9,000				10,000
Total MRD revenue			66,168				49,938				133,261				93,659
Immune Medicine revenue
Service and licensing revenue			5,385				5,001				9,166				10,123
Collaboration revenue(1)			—				3,940				—				7,540
Total Immune Medicine revenue			5,385				8,941				9,166				17,663
Total revenue		$	71,553			$	58,879			$	142,427			$	111,322

(1) On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration